Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)
International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced inoperable or metastatic non-small cell lung cancer
Non Small Cell Lung Cancer Stage IIIB|Non-Small Cell Carcinoma of Lung, TNM Stage 4
DRUG: BCD-100|DRUG: Docetaxel
Overall survival, Percent of patients who are alive after 1 year of therapy, 1 year
Overall response rate, Percent of patients who have complete or partial response to therapy, 1 year|Progression-free survival, Percent of patients who are alive after 1 year of therapy, 1 year
International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced inoperable or metastatic non-small cell lung cancer